Enantiomers, or molecule pairs that are mirror images of each other, make up more than half of FDA-approved drugs in use ...

Gilead Sciences will still supply its twice-yearly HIV prevention shot in low-income countries if it wins FDA approval ...

Congress added — and then abruptly dropped — a section of a proposed spending bill aimed at limiting the number of patents pharmaceutical manufacturers could assert in ...

India’s offer comes in the backdrop of the US administration’s stated desire to sharply reduce local drug prices, and gains ...

India has offered to supply complex generics at just 20–25 percent of the branded drug prices for the first three years after ...

Global pharma companies could ramp up pressure on India to raise the ... broader patentability criteria, and evergreening practices, Srivastava said. A pharma industry executive told The Indian ...

Trump's most-favoured nation pricing policy should be a wake-up call, as pharmaceutical companies face tighter price controls ... broader patentability criteria, and evergreening. India does not allow ...

Patent laws and market exclusivity provisions in the US also play a role. Pharmaceutical companies are granted long periods of exclusivity, and practices like 'evergreening'—making minor changes to a ...

A Cambridge-based pharmaceutical company is laying off close to a hundred employees. Ono Pharma USA, a subsidiary of the Japanese pharmaceutical company of the same name, filed with the state last ...

The UK and the EU have also sought amendments in India’s Patents Act to allow the ‘evergreening’ of patents, especially in pharma. “It is so sad that just for the supernatural profits of a select few ...

"I received requests very often that we should also allow pharmaceutical companies... to have incremental changes to their patents and allow them to have a fresh patent for another long period of time ...